Compare CLMB & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLMB | ARVN |
|---|---|---|
| Founded | 1982 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 527.7M | 600.2M |
| IPO Year | 1996 | 2018 |
| Metric | CLMB | ARVN |
|---|---|---|
| Price | $32.90 | $7.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 16 |
| Target Price | ★ $32.33 | $13.93 |
| AVG Volume (30 Days) | 135.1K | ★ 792.6K |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.13% | N/A |
| EPS Growth | 14.29 | ★ 58.84 |
| EPS | 0.48 | ★ 1.70 |
| Revenue | ★ $652,517,000.00 | $262,600,000.00 |
| Revenue This Year | $12.32 | $12.76 |
| Revenue Next Year | $9.32 | N/A |
| P/E Ratio | $70.27 | ★ $4.39 |
| Revenue Growth | ★ 40.14 | N/A |
| 52 Week Low | $15.25 | $6.97 |
| 52 Week High | $140.27 | $14.22 |
| Indicator | CLMB | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 66.67 | 30.99 |
| Support Level | $26.57 | N/A |
| Resistance Level | $129.83 | $8.52 |
| Average True Range (ATR) | 1.52 | 0.32 |
| MACD | 0.34 | -0.07 |
| Stochastic Oscillator | 82.49 | 4.23 |
Climb Global Solutions Inc is a cloud-based, value-added IT distribution and solutions company specializing in emerging technologies. It operates across the USA, Canada, United Kingdom, and Europe through multiple business units, including Climb Channel Solutions, Sigma, Grey Matter, Interwork, and TechXtend. The company is organized into two reportable operating segments. The Distribution segment distributes technical software to corporate resellers, value-added resellers (VARs), consultants, and systems integrators under the name Climb Channel Solutions. The Solutions segment is a cloud solutions provider and value-added reseller of software, hardware, and services to customers under the name Grey Matter.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.